Adult T-cell leukemia/lymphoma
| Adult T-cell leukemia/lymphoma | |
|---|---|
| Human T-cell (normal) | |
| Specialty | Oncology, hematology |
Adult T-cell leukemia/lymphoma (ATL or ATLL) is a rare cancer of the immune system's T-cells caused by human T cell leukemia/lymphotropic virus type 1 (HTLV-1). All ATL cells contain integrated HTLV-1 provirus further supporting that causal role of the virus in the cause of the neoplasm. A small number of HTLV-1 individuals progress to develop ATL with a long latency period between infection and ATL development. ATL is categorized into four subtypes: acute, smoldering, lymphoma-type, and chronic. Acute and lymphoma-type are known to be aggressive with poorer prognosis.
Globally, the retrovirus HTLV-1 is estimated to infect 20 million people per year, with the incidence of ATL approximately 0.05 per 100,000 per year. In endemic regions such as Japan, the incidence is as high as 27 per 100,000 per year. However, cases have increased in non-endemic regions with highest incidence of HTLV-1 in southern/northern islands of Japan, Caribbean, Central and South America, intertropical Africa, Romania, northern Iran. ATL usually occurs around age 62 years, but the median age at diagnosis depends on the prevalence of HTLV-1 infection in the area.
Current treatment regimens for ATL are based on clinical subtype and response to initial therapy. Some therapy modalities for treatment may not be available in all countries; therefore, strategies differ across the world. All patients are referred to clinical trials if available. Beyond clinical trials, treatments are centered on multi-agent chemotherapy, zidovudine plus interferon-a (AZT/IFN), and allogeneic hematopoietic stem cell transplantation (alloHSCT).